Executive leadership team

Dan Schneider joined Photocure November 2018. He brings more than 25 years of experience in developing and expanding rapidly growing healthcare companies in the U.S., most recently as the General Manager for Ablynx N.V. in North America. He has also held executive management positions in other pharmaceutical and biotech companies, including BTG International, Somaxon Pharmaceuticals and Sepracor. Mr. Schneider is a U.S. citizen and holds an MBA from Washington University and a Bachelor of Science degree in Business Administration from St. Louis University with a double major in Finance and Marketing. Dan Schneider holds 577,500 share options and 99,689 shares in the Company. 

Geoff Coy joined Photocure in October 2019. He has nearly 25 years of experience in the life sciences industry including sales, marketing, sales operations and market access in the biopharmaceuticals and medical device areas. Prior to joining Photocure Geoff was the Commercial Vice President of Sales and Marketing for BTG International (Boston Scientific) where he lead strategic and operational business development. Prior to BTG Geoff has been in leadership roles for Sepracor Pharmaceuticals and GlaxoSmithKline. Geoff has a proven track record and ability to build and develop high-performing commercial teams that deliver results. Geoffrey Coy holds 261,250 share options and 15,207 shares in the Company.

Anja Gossens-von der Heidt joined Photocure in February 2021 in the newly established European Organization as HR Director Europe, supporting the Global HR Foundation in her role. She was appointed Head of Global Human Resources in April 2023. 
Ms Gossens-von der Heidt brings over 20 years of HR leadership experience from different global companies, like Permobil and Haniel-Group, to the Company. Moreover, she has more than 10 years of leadership and functional responsibilities in marketing & sales, supply chain management and logistics from Pharma, Medical Device, and different Service Industries. Ms Gossens-von der Heidt holds a master’s degree in Business Administration from University Münster in Germany.
Anja Gossens-von der Heidt holds 93,000 share options in Photocure.

Jane Healy joined Photocure in March 2025 to lead the European Organization. Her extensive experience in the medical device field covers sales, marketing, general management and functional leadership, both in the UK/Ireland as well as internationally. She has worked for three major medical device organizations; St Jude Medical, CR Bard and Boston Scientific, the latter for over 20 years. 

In her most recent role, Jane was VP EMEA for the Peripheral Interventions Division for Boston Scientific, responsible for driving the growth strategy for the region. Jane brings a blend of strong commercial acumen, results orientation and a passion for enabling and driving results through her teams. 

More recently she has been building her own business as a Senior Executive Coach. Jane holds a BA (Hons) in Modern Languages from Cambridge University and she speaks English, French, German and Italian.

Jane Healy holds 140,000 share options in the Company.

Anders Neijber joined Photocure in August 2021, bringing over 25 years of substantial experience in the uro-oncology area and successful leadership in the pharmaceutical industry. He has had global and regional assignments, both in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked for Pfizer, AstraZeneca, Johnson & Johnson, Allergan and Ferring, where he held a similar global Medical Affairs leadership role as V.P., Global Therapeutic Area Head Uro-Oncology. Most recently he worked in Medical Affairs for Novartis in the Nordics. Anders completed his MD and PhD from Karolinska University, is a board certified urologist, and also holds an MBA. He held an assistant Professor position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical School, New Jersey. Anders Neijber holds 204,000 share options in Photocure.

Christopher Thibodeau brings nearly 30 years of leadership experience in molecular diagnostics and oncology, with a focus on urologic cancers and precision medicine. Most recently, he served as Chief Executive Officer of Vesica Health, where he led the development and commercialization strategy for AssureMDx, a non-invasive genomic test for bladder cancer detection and monitoring. Previously, Mr. Thibodeau served as CEO of Immunis.AI, an immunogenomics platform company leveraging machine learning to develop assays for urologic cancers. As COO of MDxHealth, he played a key role in establishing the company’s U.S. operations and supporting the clinical validation, reimbursement, guideline inclusion, and commercialization of its urology and oncology diagnostic tests and services. He has extensive experience building and scaling commercial operations across U.S. and European markets.